Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:
U.S. Feraheme product sales, net	$ 71,362	$ 58,287	$ 52,097
License fee and other collaboration revenues	8,385	26,475	8,321
Other product sales and royalties	1,109	616	831
Total revenues	80,856	85,378	61,249
Costs and expenses:
Cost of product sales	11,960	14,220	10,531
Research and development expenses	20,564	33,296	58,140
Selling, general and administrative expenses	59,949	53,071	68,863
Restructuring expenses		2,215	3,508
Total costs and expenses	92,473	102,802	141,042
Other income (expense):
Interest and dividend income, net	1,051	1,286	1,747
Gains on sale of assets	924
Gains (losses) on investments, net	40	(1,466)	(193)
Total other income (expense)	2,015	(180)	1,554
Net loss before income taxes	(9,602)	(17,604)	(78,239)
Income tax benefit		854	1,170
Net loss	$ (9,602)	$ (16,750)	$ (77,069)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.44)	$ (0.78)	$ (3.64)
Weighted average shares outstanding used to compute net loss per share:
Basic and diluted (in shares)	21,703	21,392	21,189